Kenneth Frazier - Merck Chairman

MRK -- USA Stock  

Fiscal Quarter End: December 31, 2019  

  Chairman
Mr. Kenneth C. Frazier is Chairman of the Board, President and Chief Executive Officer of the Company. Mr. Frazier previously served as Executive Vice President and President, Global Human Health of the Company and Merck Sharp Dohme Corporationration . Mr. Frazier also served as Executive Vice President and General Counsel of Merck Sharp Dohme Corporationration . Director, Exxon Mobil Corporationrationration since 2009 and Pharmaceutical Research and Manufacturers of America since 2011. Trustee, The Pennsylvania State University and Cornerstone Christian Academy in Philadelphia, PA Member, Board of Overseers of Weill Cornell Medical College and Graduate School of Medical Sciences, American Academy of Arts and Sciences, Council on Foreign Relations, the Council of the American Law Institute and the American Bar Association. Mr. Frazier has broad managerial and operational expertise and deep institutional knowledge, as well as a track record of achievement, integrity and sound judgment demonstrated prior to, and during his long tenure with Merck. In addition, his role as the Chair of the Board Affairs Committee of Exxon Mobil Corporationrationration has provided him with important experience on governance issues facing public companies.
Age: 63  Chairman Since 2011      
908-740-4000  http://www.merck.com
Frazier also served as Executive Vice President and General Counsel of Merck Sharp & Dohme Corporationrationration . Director, Exxon Mobil Corporationrationrationration since 2009 and Pharmaceutical Research and Manufacturers of America since 2011. Trustee, The Pennsylvania State University and Cornerstone Christian Academy in Philadelphia, PA; Member, Board of Overseers of Weill Cornell Medical College and Graduate School of Medical Sciences, American Academy of Arts and Sciences, Council on Foreign Relations, the Council of the American Law Institute and the American Bar Association.

Kenneth Frazier Latest Insider Activity

Management Efficiency

The company has Return on Asset of 0.13 % which means that on every $100 spent on asset it made $0.13 of profit. This is way below average. In the same way, it shows return on shareholders equity (ROE) of 0.29 % implying that it generated $0.29 on every 100 dollars invested.
The company has 27.59 B in debt with debt to equity (D/E) ratio of 99.4 . This implies that the company may be unable to create cash to meet all of its financial commitments. Merck has Current Ratio of 1.19 demonstrating that it may not be capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives

CHAIRMAN Since

Lamberto AndreottiBristol Myers Squibb Company
2015
Moncef SlaouiGlaxoSmithKline PLC
2014
Jennifer TaubertJohnson Johnson
2018
Leif JohanssonAstrazeneca PLC
2012
Ian ReadPfizer
2018
Joaquin DuatoJohnson Johnson
2018
Alex KrauerNovartis AG
N/A
Brenton SaundersAllergan Plc
2016
Ulrich LehnerNovartis AG
2006
Daniel VasellaNovartis AG
N/A
Jorge MesquitaJohnson Johnson
2016
Alex GorskyJohnson Johnson
2012
John MartinGilead Sciences
N/A
John LechleiterEli Lilly And Company
2016
Enrico VanniNovartis AG
2013
Daniel ODayGilead Sciences
2019
Thibaut MongonJohnson Johnson
2018
Paul BisaroAllergan Plc
2016
Ashley McEvoyJohnson Johnson
2018
Giovanni CaforioBristol Myers Squibb Company
2017
Sandra PetersonJohnson Johnson
2017

Entity Summary

It operates in Pharmaceutical, Animal Health, Healthcare Services, and Alliances segments. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey. Merck operates under Drug Manufacturers - Major classification in USA and is traded on BATS Exchange. It employs 69000 people.Merck Company (MRK) is traded on BATS Exchange in USA. It is located in 2000 Galloping Hill Road and employs 69,000 people. Merck Company was previously known as Merck Co and was traded on BATS Exchange under the symbol SGP. Merck is listed under Pharmaceutical Products category by Fama And French industry classification.

Merck Leadership Team

Thomas Glocer, Independent Director
Craig Thompson, Independent Director
Jennifer Zachary, Executive Vice President, General Counsel
Rochelle Lazarus, Independent Director
Michael Rosenblatt, Executive Vice President Chief Medical Officer
Wendell Weeks, Independent Director
Michael Holston, Executive Vice President Chief Ethics and Compliance Officer
Paul Rothman, Independent Director
Mary Coe, Independent Director
Adele Ambrose, Senior Vice President Chief Communications Officer
Joseph Romanelli, IR Contact Officer
Mirian GraddickWeir, Executive Vice President - Human Resources
Peter Wendell, Independent Director
John Noseworthy, Independent Director
Leslie Brun, Lead Independent Director
Julie Gerberding, Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health
Inge Thulin, Independent Director
Pamela Craig, Independent Director
Patricia Russo, Independent Director
Willie Deese, Executive Vice President and Presidentident - Merck Manufacturing Division
Rita Karachun, Principal Accounting Officer, Sr. VP of Fin. and Global Controller
Robert Davis, Executive Vice President, Global Services, Chief Financial Officer
Robert Kidder, Independent Director
Thomas Cech, Independent Director
Michael Nally, Executive Vice President, Chief Marketing Officer
Clark Golestani, CIO and Executive VP
William Harrison, Lead Independent Director
Roger Perlmutter, Executive Vice President and Presidentident - Merck Research Laboratories
Ashley Watson, Senior Vice President Chief Ethics and Compliance Officer
Steven Mizell, Executive Vice President, Chief Human Resources Officer, Human Resources
Jim Scholefield, Executive Vice President, Chief Information and Digital Officer
Sanat Chattopadhyay, Executive Vice President and President - Merck Manufacturing Division
Adam Schechter, President of Global Human Health and Executive VP
Carlos Represas, Independent Director
Richard DeLuca, Executive Vice President and Presidentident - Merck Animal Health
Kenneth Frazier, Chairman of the Board, President, Chief Executive Officer
Frank Clyburn, Executive Vice President, Chief Commercial Officer

Stock Performance Indicators

Current Sentiment - MRK

Merck Investor Sentiment

Predominant part of Macroaxis users are now bullish on Merck Company. What is your trading attitude regarding investing in Merck Company? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see also Stocks Correlation. Please also try Market Hitters module to find equities that experience drastic asymmetry in trading patters, price, volume, or investment outlook..
Search macroaxis.com